| 512.69 -11.61 (-2.21%) | 04-10 12:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 668.32 | 1-year : | 780.6 |
| Resists | First : | 572.2 | Second : | 668.32 |
| Pivot price | 501.97  |
|||
| Supports | First : | 477.34 | Second : | 418.72 |
| MAs | MA(5) : | 519.76  |
MA(20) : | 487.73 |
| MA(100) : | 511.56 |
MA(250) : | 421.28 |
|
| MACD | MACD : | 18.2 |
Signal : | 15.4 |
| %K %D | K(14,3) : | 60.4 |
D(3) : | 62.5 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 615 | Low : | 265 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MDGL ] has closed below upper band by 44.8%. Bollinger Bands are 52.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 526.34 - 528.36 | 528.36 - 530.69 |
| Low: | 505.16 - 507.32 | 507.32 - 509.81 |
| Close: | 520.21 - 523.74 | 523.74 - 527.8 |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Fri, 10 Apr 2026
What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN
Thu, 09 Apr 2026
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - simplywall.st
Tue, 07 Apr 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 06 Apr 2026
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) - MSN
Tue, 31 Mar 2026
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - Sahm
Fri, 27 Mar 2026
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 3,930 (K) |
| Shares Short P.Month | 3,620 (K) |
| EPS | -12.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.38 |
| Profit Margin | -30.1 % |
| Operating Margin | -18.6 % |
| Return on Assets (ttm) | -16.3 % |
| Return on Equity (ttm) | -42.5 % |
| Qtrly Rev. Growth | 210.8 % |
| Gross Profit (p.s.) | 39.33 |
| Sales Per Share | 41.77 |
| EBITDA (p.s.) | -13.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -190 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -39.55 |
| PEG Ratio | 0 |
| Price to Book value | 19.28 |
| Price to Sales | 12.18 |
| Price to Cash Flow | -61.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|